Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

Tasci, Elif SenocakOyan, BasakSonmez, OzlemMutlu, Arda UlasAtci, Muhammed MustafaOner, IremCinkir, Havva Yesil2024-02-232024-02-2320220732-183X1527-7755https://doi.org/10.1200/JCO.2022.40.4_suppl.202https://hdl.handle.net/20.500.12452/15089ASCO Gastrointestinal Cancers Symposium -- JAN 20-22, 2022 -- San Francisco, CA[Abstract Not Availabe]eninfo:eu-repo/semantics/closedAccess[Keyword Not Available]Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group studyConference Object404Q1WOS:000770995900198Q110.1200/JCO.2022.40.4_suppl.202